Science Signaling,
Journal Year:
2020,
Volume and Issue:
13(639)
Published: July 7, 2020
Reactive
oxygen
species
(ROS)
are
physiological
mediators
of
cellular
signaling
and
play
potentially
damaging
roles
in
human
diseases.
In
this
study,
we
found
that
the
catalytic
activity
Ser/Thr
kinase
Aurora
A
was
inhibited
by
oxidation
a
conserved
cysteine
residue
(Cys
Journal of the American Chemical Society,
Journal Year:
2021,
Volume and Issue:
143(48), P. 20095 - 20108
Published: Nov. 24, 2021
Chemical
modifications
of
native
proteins
can
affect
their
stability,
activity,
interactions,
localization,
and
more.
However,
there
are
few
nongenetic
methods
for
the
installation
chemical
at
a
specific
protein
site
in
cells.
Here
we
report
covalent
ligand
directed
release
(CoLDR)
site-specific
labeling
strategy,
which
enables
variety
functional
tags
on
target
while
releasing
directing
ligand.
Using
this
approach,
were
able
to
label
various
such
as
BTK,
K-RasG12C,
SARS-CoV-2
PLpro
with
different
tags.
For
BTK
have
shown
selective
cells
both
alkyne
fluorophores
Protein
by
traditional
affinity
often
inhibits
activity
since
permanently
occupies
binding
pocket.
We
that
using
CoLDR
chemistry,
modification
these
probes
preserves
its
activity.
demonstrated
several
applications
approach
including
determining
half-life
environment
minimal
perturbation,
well
quantification
degradation
noncovalent
proteolysis
targeting
chimera
(PROTAC)
in-gel
fluorescence.
an
environment-sensitive
"turn-on"
fluorescent
probe,
monitor
active
BTK.
Finally,
efficient
CoLDR-based
PROTACs
(DC50
<
100
nM),
installed
CRBN
binder
onto
This
joins
very
available
strategies
maintain
thus
makes
important
addition
toolbox
biology.
Angewandte Chemie International Edition,
Journal Year:
2021,
Volume and Issue:
60(31), P. 17131 - 17137
Published: May 19, 2021
Abstract
Targeted
covalent
inhibitors
have
re‐emerged
as
validated
drugs
to
overcome
acquired
resistance
in
cancer
treatment.
Herein,
by
using
a
carbonyl
boronic
acid
(CBA)
warhead,
we
report
the
structure‐based
design
of
BCR‐ABL
via
reversible
targeting
catalytic
lysine
with
improved
potency
against
both
wild‐type
and
mutant
ABL
kinases,
especially
T315I
bearing
gatekeeper
residue
mutation.
We
show
evolutionarily
conserved
can
be
targeted
selectively,
selectivity
depends
largely
on
molecular
recognition
non‐covalent
pharmacophore
this
class
inhibitors,
probably
due
moderate
reactivity
warhead.
first
co‐crystal
structures
inhibitor‐ABL
kinase
domain
complexes,
providing
insights
into
interaction
warhead
lysine.
also
employed
label‐free
mass
spectrometry
evaluate
off‐targets
our
compounds
at
proteome‐wide
level
different
mammalian
cells.